"Jinzheng Research" Northern Capital Center Chi Yuan / Author Izumo Yingwei / Risk Control
In 2018, Shanghai Mengke Pharmaceutical Co., Ltd. (hereinafter referred to as "Mengke Pharmaceutical") submitted a prospectus to the Hong Kong Stock Exchange twice, both of which ended in failure.At the end of 2020, Mengke Pharmaceutical restarted its listing plan, intending to hitthe Science and Technology Innovation Board.On June 1, 2021, Contezolid Tablets (hereinafter referred to as "contezolid"), a new drug independently developed by Mengke Pharmaceutical, was approved for marketing. So far, it is the only one of the above-mentioned products.
Not only that, JINQIAN LIU (Liu Jinqian), as the core technician of Mengke Pharmaceutical, is responsible for the pipeline research and development of Mengke Pharmaceutical, and is the head of the chemical department.Liu Jinqian joined Mengke Pharmaceutical in October 2007 after resigning from his old owner, Amgen Inc (hereinafter referred to as "Amgen").The strange thing is that in the patent applications of Amgen in 2008 and 2010, the inventors list may be Liu Jinqian, and Liu Jinqian appeared as one of the authors in the article published by Amgen in 2016.And given that Mengke Pharmaceutical's drug research direction may overlap with Liu Jin's former employer, is Liu Jinqian still involved with his former employer?In addition, it is worth mentioning that Mengke Pharmaceutical is suspected of selective disclosure of information on the appointment and shareholding of independent directors, and the directors’ resumes disclosed in its prospectus are frequently inconsistent with official information, and the quality of information disclosure may be “discounted”.
1. The core technical personnel appear on the list of patent inventors of the old company, and the relationship may be "unclear"
Core technicians are an important part of the company's personnel composition. It is worth noting that a core technician of Mengke Pharmaceutical may still participate in the patent research and development of its "former owner" after joining the company.
It should be pointed out that JINQIAN LIU (Liu Jinqian) is the core technical staff of Mengke Pharmaceutical.
According to the prospectus signed by Mengke Pharmaceutical on March 31, 2022 (hereinafter referred to as the "Prospectus"), as of March 31, 2022, the date of signing the prospectus, JINQIAN LIU (Liu Jinqian) is the core technical staff of Mengke Pharmaceutical .
According to the prospectus, Mengke Pharmaceutical has obtained a total of 19 invention patents in China, the United States, Europe, Japan, Canada and other countries and regions, including 8 domestic authorized patents and 11 overseas authorized patents.
According to the Reply to the Inquiry Letter for the Second Round Review of the Application Documents for the Initial Public Offering and Listing on the Science and Technology Innovation Board of Mengke Pharmaceutical Co., Ltd. signed on February 21, 2022 (hereinafter referred to as the "Second-round Inquiry Letter") Inquiry and Reply”), Mengke Pharmaceutical has an invention patent named “Water-soluble (O-carbonyl) phosphoramidate prodrug for therapeutic use”, its patent number is ZL201580001343.2, and the patent name of its foreign invention patent of the same family is "Water-soluble O-carbonyl phosphoramidate prodrugs for therapeutic administration", patent number US9382276.
The application date of the above two patents is February 20, 2015, and the inventors are MIKHAIL FEDOROVICH GORDEEV, Liu Jinqian, Wang Xinghai, ZHENGYU YUAN (Yuan Zhengyu).
According to the replies to the second round of inquiries, Kerui Kesi (Beijing) PharmaceuticalCo., Ltd., a subsidiary of Mengke Pharmaceutical, has an invention patent called "Tricyclic Boron Compounds that Can Be Used for Antibacterial Therapy", and its patent number is ZL201280064147. 6. The patent name of its foreign invention patent of the same family is "Tricyclic boron compounds for antimicrobial therapy", the patent number is US8530452, and the patentee is Mengke Pharmaceutical.The two patent families were filed on December 20, 2012, and the inventors of the patents are MIKHAIL FEDOROVICH GORDEEV, Liu Jinqian, Wang Xinghai, and Yuan Zhengyu.
According to the replies to the second round of inquiries, Mengke Pharmaceutical has an invention patent called "polymyxin antibacterial agent for the treatment of bacterial infections", its patent number is ZL201580075652.4, and the patent name of its overseas invention patent of the same family is "Antimicrobial polymyxins for treatment of bacterial infections", patent number US9771394.The two patent families were filed on December 16, 2015, and the inventors of the patents are MIKHAIL FEDOROVICH GORDEEV, Liu Jinqian, Wang Xinghai, and Yuan Zhengyu.
It is worth noting that a number of patents that Liu Jinqian participated in the research and development of Mengke Pharmaceuticals are also one of the patents transferred to Mengke Pharmaceuticals for investment by the shareholders of Mengke Pharmaceuticals.
According to the prospectus, as of January 1, 2019, MicuRx (HK) Limited (hereinafter referred to as "Mengke Hong Kong") held an 83.91% stake in Shanghai Mengke Pharmaceutical Co., Ltd. (hereinafter referred to as "Mengke Co., Ltd.").
According to the prospectus, in the first capital increase of Mengke Co., Ltd. during the reporting period, on August 18, 2020, its board of directors decided to agree that Mengke Hong Kong will evaluate 18 patented technologies including patent application rights at a price of 416 million yuan. Mengke Co., Ltd. increased capital, of which 415 million yuan was included in the registered capital of Mengke Co., Ltd., and the remaining 584,200 yuan was included in the capital reserve of Mengke Co., Ltd. The registered capital of Mengke Co., Ltd. increased from 226 million yuan to 642 million yuan.
After the "Business License" was renewed on August 27, 2020, through this capital increase, Mengke Hong Kong held 94.33% of the shares of Mengke Pharmaceutical.
According to the replies to the second round of inquiries, in August 2020, the patented technology of Mengke Hong Kong's capital increase in Mengke Pharmaceutical includes 8 patents and 10 patent application rights.It includes three authorized patents with patent numbers US9382276, US8530452 and US9771394.
It is not difficult to see that the three overseas patents that Liu Jinqian participated in research and development were all used by Mengke Hong Kong to increase the capital of Mengke Pharmaceutical in 2020.
However, during Liu Jinqian's tenure in Union Science Pharmaceuticals, he appeared among the patent inventors of his former company.
According to the prospectus, from March 2004 to October 2007, Liu Jin worked as a scientist at Amgen and participated in the research and development of anti-tumor, anti-inflammatory and anti-diabetic drugs.From November 2007 to the prospectus signing date March 31, 2022, Liu Jinqian served as the head of the chemical department of Mengke Pharmaceutical, responsible for the research and development of the pipeline of Mengke Pharmaceutical, and was one of the main inventors of the invention patent of Mengke Pharmaceutical. Over 30 years of experience in drug discovery and related fields, with more than 20 research papers published in peer-reviewed scientific and pharmaceutical industry journals.
According to the U.S. National Library of Medicine, "Discovery of the imidazole-derived GPR40 agonist AM-3189" published by Elsevier on January 1, 2016, the authors of the article are all affiliated with Amgen, and the author cohort includes Jinqian Liu, of whom Jinqian Liu Liu is part of Amgen's Therapeutic Discovery Division.The electronic version of this article was published on November 17, 2015.
According to Elsevier's official website, "Discovery of the imidazole-derived GPR40 agonist AM-3189" was received on August 10, 2015, revised on November 9, 2015, and available online on November 17, 2015 , the record version dated December 8, 2015, and published in Bioorganic & Medicinal Chemistry Letters on January 1, 2016.
AM-3189, a follow-up to the GPR40 agonist AMG 837, was evaluated in clinical trials for the treatment of type 2 diabetes, according to an abstract from the U.S. National Library of Medicine, Discovery of the imidazole-derived GPR40 agonist AM-3189. Its further optimization led to the discovery of AM-3189 (13k).AM-3189 is representative of a new class of compounds with CNS penetration comparable to AMG 837, excellent pharmacokinetic properties and in vivo efficacy.
It can be seen that the above article "Discovery of the imidazole-derived GPR40 agonist AM-3189" involves a GPR40 agonist, which is related to the development of drugs for the treatment of diabetes, and one of the authors of the article "Jinqian Liu" not only has the same English spelling as Liu Jinqian , and the affiliated unit is also Amgen, Liu Jinqian's old club.This means that Liu Jinqian, a core technician of Mengke Pharmaceutical, may be one of the authors of the academic article "Discovery of the imidazole-derived GPR40 agonist AM-3189" published in 2016, that is, Liu Jinqian, an employee of Amgen's treatment discovery department.
Not only that, after joining Mengke Pharmaceutical, Liu Jinqian's "figure" may also be seen among Amgen's patent inventors.
According to the prospectus, MicuRx Pharmaceuticals, Inc. (hereinafter referred to as "Monco Cayman") is an indirect shareholder of MicuRx Pharmaceuticals and holds 100% of the shares of MicuK Hong Kong.
According to the prospectus, in June 2007, Monco Cayman registered and established MicuRx Pharmaceuticals, Inc. (hereinafter referred to as "Monco America") in California, USA, with an authorized share capital of 100 shares, which is a wholly-owned subsidiary of Monco Cayman.In 2020, Mengke Pharmaceutical acquired 100% equity of Mengke America.
According to the prospectus, Liu Jinqian also worked in Mengke America.
According to the data of the United States Intellectual Property Office, a patent application titled "Antimicrobial heterocyclic compounds for treatment of bacterial infections" is assigned to Mengke Cayman, the patent application number is US20120157434, and the application date is February 29, 2008. The inventors of the patent application include Liu Jinqian.Among them, Liu Jinqian belongs to "Palo Alto, CA".
According to the data of the United States Intellectual Property Office, Amgen has a patent titled "Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions", the patent number is US8785468, the patent application date is February 12, 2010, and the authorization announcement date is On July 22, 2014, the inventors of the patent included Liu Jinqian.Among them, Liu Jinqian belongs to "Palo Alto, CA".
It is not difficult to see that both Liu Jinqian, the inventor of a patent application filed by Mengke Cayman, and Liu Jinqian, the inventor of the patent applied for by Amgen on February 12, 2010, belong to Palo Alto, California, and they may be the same person.It can be seen that Liu Jinqian, who resigned from Amgen in 2007, appeared again in the list of inventors in Amgen's patent applications in 2008 and 2010, and appeared in Amgen's published articles in 2016 or as one of the authors.
It should be pointed out that the related research and development that Liu Jinqian participated in at Amgen may overlap with the research and development direction of Mengke Pharmaceutical.
According to the prospectus, Mengke Pharmaceutical is aninnovative drugcompany focusing on the treatment of infectious diseases and is committed to the discovery, development and commercialization of innovative drugs for unmet clinical needs.Since its inception, Mengke Pharmaceutical has been focusing on the growing problem of bacterial drug resistance in the world.
According to the prospectus, Mengke's product pipeline mainly focuses on the treatment of drug-resistant Gram-positive and Gram-negative bacterial infections. As of March 31, 2022, the date of the prospectus, Mengke's commercialized products and clinical stage drugs A total of 3 models, namely cantezolid, MRX-4, MRX-8.
According to the prospectus, Contezolid, the first antibacterial product of Mengke Pharmaceutical, is a new generation of oxazolidinone antibacterial drugs, which can be used to treat infections caused by multi-drug resistant Gram-positive bacteria.MRX-4 is a water-soluble prodrug of contezolid, which is converted into contezolid to exert its curative effect in vivo.MRX-8 is a drug for the treatment of multidrug-resistant gram-negative bacterial infections.In addition to the above three core products that have entered the clinical stage and/or the commercialization stage, Mengke Pharmaceutical also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-COVID-19 drugpipelinesin the preclinical stage .
According to the prospectus, indications for MRX-4 include diabetic foot infections.Diabetic foot infection is a chronic complication of severe diabetes and high treatment costs. It is a disease caused by Gram-positive bacteria. The common pathogens are MRSA or other Streptococcus bacteria.
That is to say, Mengke Pharmaceutical is committed to the research and development of new drugs for the treatment of drug-resistant bacterial infections, and its product pipeline also involves kidney cancer, nephritis drugs and anti-new crown drug pipelines.
According to Amgen's official website, Amgen has long focused on the exploration, research and development, production and sales of innovative human drugs.In China, Amgen focuses on chronic diseases that urgently need to be addressed, such as cardiovascular disease, bone health, inflammation, and kidney disease, to provide patients with innovative treatment options.
It is not difficult to see that Amgen focuses on the R&D and production of new drugs in the fields of cardiovascular disease, bone health, inflammation, kidney disease and other chronic diseases, while Mengke Pharmaceutical's products under development include kidney cancer and nephritis drugs.In addition, Liu Jin previously participated in the research and development of anti-tumor, anti-inflammatory and anti-diabetic drugs at Amgen, and the indications of MRX-4, the product under development of Mengke Pharmaceutical, mainly include diabetic foot infection, a complication of diabetes.
So far, the prospectus stated that Liu Jinqian joined Mengke Pharmaceutical in the month following his resignation from Amgen in October 2007.The strange thing is that in the patent applications of Amgen in 2008 and 2010, the inventors list may be Liu Jinqian, and Liu Jinqian appeared as one of the authors in the article published by Amgen in 2016.In November 2007, did Liu Jinqian leave Amgen when he joined Mengke Pharmaceutical?If he has resigned, why did Liu Jinqian appear in the list of patent inventors and article authors of his old employer Amgen after he resigned?And given that Mengke Pharmaceutical's drug research direction overlaps with that of Amgen, is Liu Jinqian still unclear about his "old club"?What is the impact of Amgen on Liu Jinqian's drug development?Doubt remains.
2. The independent directors and part-time companies are hidden and undeclared, and the directors' resumes and "official announcements" are stored and withdrawn to question the quality of letters and disclosures
Information disclosure has always been the focus of the regulators' attention, and Mengke's disclosure of the part-time position of its directors has "confronted" with the official in many places.
According to the prospectus, as of March 31, 2022, the date when the prospectus was signed, Chen Daijie has served as an independent director of Mengke Pharmaceutical since December 2020.From April 2004 to April 2017, Chen Daijieworked as a researcher and vice president of Shanghai PharmaceuticalIndustry Research Institute.Since May 2017, Chen Daijie has been a Distinguished Professor at Shanghai Jiao Tong University.
According to the prospectus, as of March 31, 2022, the date when the prospectus was signed, in addition to working in Shanghai Pharmaceutical Industry Research Institute and Shanghai Jiaotong University, Chen Daijie also holds a stake in Zhejiang Microtech Environmental Restoration Engineering Co., Ltd. (hereinafter referred to as "Microtech Environment"). ”) 46% stake.
In fact, the company that Chen Daijie, an independent director of Mengke Pharmaceutical, holds shares abroad or not only Microtech Environment.
According to the data of the Market Supervision Administration, Shanghai Laiyi Biological Drug Research and Development Center Co., Ltd. (hereinafter referred to as "Laiyi Bio") was established on December 3, 2001, and its business scope is the research, development and related fields of biological drugs. technical services, technology development, technology consulting, technology transfer.As of May 23, 2022, the date of inquiry, "Chen Daijie" is the shareholder and general manager of Laiyi Bio, with a shareholding ratio of 20%.
According to the data of the Market Supervision and Administration Bureau, on March 9, 2016 and September 23, 2021, Laiyi Biological changed its shareholders. Before and after the two changes, "Chen Daijie" was a shareholder of Laiyi Bio.In addition, as of May 23, 2022, the date of inquiry, Laiyi Bio has no other record of equity change in "Chen Daijie".
According to public information, as of May 23, 2022, the date of inquiry, Chen Daijie, an independent director of Mengke Pharmaceutical, also holds positions and shares in Laiyi Biotech, where he holds the position of general manager and holds 20% of the shares.That is to say, Chen Daijie, the independent director of Mengke Pharmaceutical, is the same person as the general manager and shareholder "Chen Daijie" of Laiyi Biology.
According to the official website information released by Shanghai Jiao Tong University on May 28, 2021, from 2001 to 2004, Chen Daijie served as the director of the drug research center of Laiyi Bio.
That is to say, according to the data of the Market Supervision Administration, as of May 23, 2022, the date of inquiry, Chen Daijie, an independent director of Mengke Pharmaceutical, may also serve as the general manager of Laiyi Bio and hold 20% equity of Lai Yi Bio, while the prospectus This was not disclosed.
In addition, Mengke Pharmaceutical's disclosure of the appointment information of its other director is also inconsistent with official information.
According to the prospectus, from December 2020 to March 31, 2022, the date when the prospectus was signed, Duan Jian served as the director of Mengke Pharmaceutical.From July 2016 to March 2019, Duan Jian worked as a freelancer.From April 2019 to present, Duan Jian has served as the executive director of BioVida Investment Consulting (Shanghai) Co., Ltd. (hereinafter referred to as "BIO Consulting").
According to the data of the Market Supervision and Administration Bureau, Baiao Consulting was established on October 27, 2005. Its business scope includes investment consulting, business management consulting,tradeinformation consulting, andinternational economicconsulting.As of the enquiry date on 5/23/2022, Yang Zhi served as the executive director of Baiao Consulting.
According to the data of the Market Supervision and Administration Bureau, on April 5, 2016, Baiao Consulting conducted the filing of its legal representative and supervisor. Before and after the change of its legal representative, Yang Zhi was the same as Li Hua, and Li Hua was changed to the supervisor of Baiao Consulting.In addition, as of May 23, 2022, the date of inquiry, BIO Consulting has no other personnel information changes.
It can be seen that Mengke Pharmaceutical stated in its prospectus that director Duan Jianyu served as the executive director of Baiao Consulting.As of May 23, 2022, the date of inquiry, Baiao Consulting had no information on Duan Jian's appointment and appointment change, and his executive director was another person.
It is worth noting that the part-time information of Miao Yu, director of Mengke Pharmaceutical in the prospectus, also contradicts the official information.
According to the prospectus, from August 2020 to March 31, 2022, the date of the prospectus signing, Miao Yu will serve as the director of Mengke Pharmaceutical.Since April 2015, Miao Yu has been the managing director ofShanghaiJinpuMedical and HealthEquityInvestment FundManagement Co., Ltd. (hereinafter referred to as "Jimpo Medical").
According to data from the Market Supervision Administration, Gimpo Medical was established on April 20, 2015, and its business scope is equity investment management and industrial investment.On February 19, 2016, Gimpo Medical made a change in the filing of supervisors, and Miao Yu became its supervisor.On November 16, 2021, Miao Yu ceased to be the supervisor of Gimpo Medical.As of May 23, 2022, the date of inquiry, Gimpo Medical has no other employment information.
It can be seen that the prospectus stated that Miao Yu, director of Mengke Pharmaceutical, served as the managing director of Gimpo Medical from April 2015 to March 31, 2022, the date when the prospectus was signed. In fact, Miao Yu’s position in Gimpo Medical was supervisor. , and will no longer serve as a supervisor of Gimpo Medical on November 16, 2021.
That is to say, Mengke Pharmaceutical not only disclosed or did not disclose the part-time job information of independent director Chen Daijie in detail, but also the part-time information of its directors Duan Jian and Miao Yu disclosed in its prospectus was "dissimilar" from official information. The quality of information disclosure may be "tortured".
Faced with the above problems, how will Mengke Pharmaceutical "stand out" in the industry competition?or time required.
(Responsible editor: RobotRF13015)
